慢性肠衰竭患者使用富含ω-3脂肪酸的MCT/LCT脂肪乳剂进行家庭肠外营养:HOME随机对照多中心国际临床试验方案
HOME研究是一项前瞻性、随机、对照、双盲、多中心国际临床试验,计划在欧洲收治家庭肠外营养(HPN)患者的医院纳入160例慢性肠衰竭(CIF)患者,按1:1随机接受富含n-3多不饱和脂肪酸(n-3 PUFA)的中/长链甘油三酯(MCT/LCT)脂肪乳剂或标准MCT/LCT脂肪乳剂,预期干预8周。主要终点为肝功参数(总胆红素、天冬氨酸转氨酶、丙氨酸转氨酶)从基线至末次访视的复合变化,旨在评估富含n-3 PUFA脂肪乳剂在HPN患者中的安全性、耐受性及对肝功能的保护作用。
要点
- HPN患者使用静脉脂肪乳剂可能增加肠衰竭相关肝病(IFALD)风险。
- 富含n-3 PUFA的MCT/LCT脂肪乳剂或可预防HPN患者IFALD。
- HOME研究为双盲RCT,主要终点为肝功三项复合变化。
核心结论
- 富含n-3 PUFA的脂肪乳剂在HPN患者中的安全性、耐受性及对肝功能的影响尚需RCT验证。
- HOME研究预期提供可靠数据以支持n-3 PUFA脂肪乳剂在HPN中的应用。
研究设计与样本
- 前瞻性、随机、对照、双盲、多中心国际临床试验,在欧洲收治HPN患者的医院开展。
- 计划纳入160例慢性肠衰竭患者,每组80例,随机接受富含n-3 PUFA的MCT/LCT脂肪乳剂或标准MCT/LCT脂肪乳剂,预期8周。
关键数值与推荐
- 主要终点为肝功参数(总胆红素、天冬氨酸转氨酶、丙氨酸转氨酶)从基线至末次访视的复合变化。
- 次要目标为进一步评估脂肪乳剂的安全性和耐受性及疗效。
临床怎么用
- 为HPN患者选择脂肪乳剂时需权衡IFALD风险与n-3 PUFA的潜在获益。
- 在RCT结果公布前,n-3 PUFA脂肪乳剂在HPN中的应用应结合现有有限证据个体化决策。
局限性
- 目前关于HPN患者使用脂肪乳剂的RCT极少,n-3 PUFA数据非常有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Home parenteral nutrition (HPN) is a life-preserving therapy for patients with chronic intestinal failure (CIF) indicated for patients who cannot achieve their nutritional requirements by enteral intake. Intravenously administered lipid emulsions (ILEs) are an essential component of HPN, providing energy and essential fatty acids, but can become a risk factor for intestinal-failure-associated liver disease (IFALD). In HPN patients, major effort is taken in the prevention of IFALD. Novel ILEs containing a proportion of omega-3 polyunsaturated fatty acids (n-3 PUFA) could be of benefit, but the data on the use of n-3 PUFA in HPN patients are still limited. METHODS/DESIGN: The HOME study is a prospective, randomized, controlled, double-blind, multicenter, international clinical trial conducted in European hospitals that treat HPN patients. A total of 160 patients (80 per group) will be randomly assigned to receive the n-3 PUFA-enriched medium/long-chain triglyceride (MCT/LCT) ILE (Lipidem/Lipoplus® 200 mg/ml, B. Braun Melsungen AG) or the MCT/LCT ILE (Lipofundin® MCT/LCT/Medialipide® 20%, B. Braun Melsungen AG) for a projected period of 8 weeks. The primary endpoint is the combined change of liver function parameters (total bilirubin, aspartate transaminase and alanine transaminase) from baseline to final visit. Secondary objectives are the further evaluation of the safety and tolerability as well as the efficacy of the ILEs. DISCUSSION: Currently, there are only very few randomized controlled trials (RCTs) investigating the use of ILEs in HPN, and there are very few data at all on the use of n-3 PUFAs. The working hypothesis is that n-3 PUFA-enriched ILE is safe and well-tolerated especially with regard to liver function in patients requiring HPN. The expected outcome is to provide reliable data to support this thesis thanks to a considerable number of CIF patients, consequently to broaden the present evidence on the use of ILEs in HPN. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03282955. Registered on 14 September 2017.
引用
- Klek S, Chambrier C, Cooper SC, et al. Home parenteral nutrition with an omega-3-fatty-acid-enriched MCT/LCT lipid emulsion in patients with chronic intestinal failure (the HOME study): study protocol for a randomized, controlled, multicenter, international clinical trial. Trials. 2019. PMID: 31888740. doi:10.1186/s13063-019-3994-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。